Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NeoGenomics Laboratories (NEO)

NeoGenomics Q2 revenue up 10% to $181 million; 2025 revenue outlook cut

Negative Impact 4 of 5 guidance Written later

NeoGenomics reported second-quarter 2025 revenue of $181 million, up 10% from a year earlier, but its net loss widened to $45 million, including $20 million of impairment charges. The company also lowered its full-year 2025 revenue guidance to $720 million to $726 million from $747 million to $759 million, and widened its expected net loss, which matters to shareholders because it signals weaker results than previously expected.

Key points

  • Q2 2025 revenue rose 10% to $181 million; clinical revenue grew 16%, or 13% excluding Pathline
  • Q2 net loss increased 142% to $45 million, including $20 million of impairment charges; Adjusted EBITDA was $10.7 million, flat year over year
  • 2025 revenue guidance lowered to $720 million-$726 million from $747 million-$759 million
  • 2025 GAAP net loss guidance widened to $(116) million-$(108) million from $(85) million-$(77) million

The filing

CompanyNeoGenomics Laboratories (NEO)
Form8-K, current report
Filed with the SECJul 29, 2025, 7:08 AM ET
Accession number0001077183-25-000151

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.